TRINETRA › Sectors › Healthcare
Lupin Limited (LUPIN) — share price, P/E and fundamentals
Lupin Limited (NSE: LUPIN) closed at ₹2,011.00 on 30 Oct 2026, +3.7% over one year, against a 52-week range of ₹1,892.90 – ₹2,529.50.
In the quarter ended 30 Jun 2026 (consolidated, filed 6 Aug 2026) it reported revenue of ₹8,277 cr and net profit of ₹1,415 cr, a 17.1% net margin; revenue grew 32.0% and profit grew 42.5% year on year.
On four consecutive filed quarters its trailing P/E is 16.6; since 15 May 2025 its own P/E has ranged from 15.7 to 30.8 (median 26.3), and today's reading is higher than 3% of those 361 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 25.2%, ROCE 33.1%, debt-to-equity 0.26, Piotroski F-score 8 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 64% of 63 sector peers; PBT margin higher than 70% of 63 sector peers; ROE higher than 87% of 63 sector peers.
Key figures
| Last close | ₹2,011.00 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -4.3% / -12.4% / +3.7% |
| 52-week low – high | ₹1,892.90 – ₹2,529.50 |
| Market capitalisation | ₹91,953 cr |
| Trailing P/E | 16.6 |
| Price / book | 4.10 |
| EV / EBITDA | 9.9 |
| Earnings yield | 6.0% |
| TTM EPS | ₹120.91 |
| TTM net profit | ₹5,529 cr |
| Quarter revenue | ₹8,277 cr |
| Quarter net profit | ₹1,415 cr |
| Net margin | 17.1% |
| Revenue growth (YoY) | +32.0% |
| Profit growth (YoY) | +42.5% |
| Return on equity | 25.2% |
| ROCE | 33.1% |
| Debt / equity | 0.26 |
| Current ratio | 1.90 |
| Free cash flow | ₹5,491 cr |
| Piotroski F-score | 8 / 9 |
| Average daily turnover (50 days) | ₹131.2 cr |
Against Healthcare peers
| Metric | LUPIN | Peer median | Percentile |
|---|---|---|---|
| Net margin | 17.10 | 12.67 | 64 |
| PBT margin | 24.37 | 17.57 | 70 |
| ROE | 25.21 | 13.86 | 87 |
| ROCE | 33.09 | 16.59 | 89 |
| Debt / equity | 0.26 | 0.11 | 68 |
| Cash conversion | 1.41 | 1.25 | 62 |
| Trailing P/E | 16.63 | 43.26 | 5 |
| P/B | 4.10 | 6.02 | 26 |
Questions
What is the P/E ratio of Lupin Limited?
Lupin Limited's trailing P/E is 16.6, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 15 May 2025 its P/E has ranged 15.7–30.8.
What were Lupin Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Lupin Limited reported revenue of ₹8,277 cr and net profit of ₹1,415 cr (consolidated), filed with the exchange on 6 Aug 2026.
What is Lupin Limited's ROE?
Return on equity is 25.2% based on the balance sheet dated 31 Mar 2026.
Does Lupin Limited have debt?
Debt-to-equity is 0.26 on the balance sheet dated 31 Mar 2026.
What is LUPIN's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, LUPIN traded between ₹1,892.90 and ₹2,529.50.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Max Healthcare Institute Limited (MAXHEALTH)
- Glenmark Pharmaceuticals Limited (GLENMARK)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.